MINERALYS THERAPEUTICS INC

Mineralys Therapeutics CEO sells 10,700 shares in a rule‑based, modest‑volume move—indicating portfolio management, not a negative signal for the biopharma’s future.

Mineralys insider buying: Rodman Malcom’s Rule 10b5‑1 trades stay neutral, reinforcing long‑term confidence amid an 88% rally and a promising aldosterone pipeline.

Mineralys insider trading insights: Rodman Malcom’s balanced buys/sells via a Rule 10b‑5‑1 plan reveal a cautious stance amid volatile stock and pending Q3 2026 clinical results. Click for the full analysis.

CEO Congleton Jon’s structured Rule 10b‑5‑1 sales at Mineralys reveal disciplined trading amid a 117% YTD rally—insider moves, market momentum, and pipeline prospects unpacked.

RA Capital’s surge in Mineralys Therapeutics shares signals a bullish insider‑buying trend, highlighting the biopharma’s pipeline potential and market confidence.

Mineralys Therapeutics insider activity: CMO Rodman Malcom’s balanced buys, sells, and options show steady stake, confidence in a niche aldosterone pipeline despite losses.

Mineralys insider RSU grant shows executive confidence in its ASI pipeline—learn how this could lift stock momentum and what to watch for next.

RA Capital’s fresh 6,200‑share purchase signals growing institutional confidence in Mineralys Therapeutics, bolstering the drug‑pipeline’s upside potential.

Mineralys insider buying signals confidence, but investors should watch upcoming clinical milestones to confirm a rebound in the biopharma stock.

Mineralys Therapeutics insider trades reveal CMO confidence amid heavy exec selling – understand the impact on stock value, liquidity, and future outlook.